Financial Benefits of Renal Dose-Adjusted Dipeptidyl Peptidase-4 Inhibitors for Patients with Type 2 Diabetes and Chronic Kidney Disease.

Hun Jee ChoeYeh-Hee KoSun Joon MoonChang Ho AhnKyoung Hwa HaHyeongsuk LeeJae Hyun BaeHyung Joon JooHyejin LeeJang Wook SonDae Jung KimSin Gon KimKwangsoo KimYoung Min Cho

Published in: Endocrinology and metabolism (Seoul, Korea) (2024)

Adjusting the doses of RDA DPP4 inhibitors based on individual kidney function could alleviate the economic burden associated with medical expenses.

Keyphrases

chronic kidney disease
end stage renal disease
healthcare
young adults
peritoneal dialysis